Moreover, in the VISION trial the efficacy and safety of tepotinib in a sub-group of elderly patients (over 75 years old) with NSCLC characterized by MET exon 14-altered resulted similar to the other enrolled patients (ORR 39.7%, 95% CI 28–52.3; median PFS 8.6 months, 95% CI 6.9–12.4) [9]. This evidence concerns the gene MET and non-small cell lung carcinoma.